Efficacy of Siltuximab in Patients with Previously Treated Multicentric Castleman’s Disease (MCD).

Frits Van Rhee,Nikhil C. Munshi,Raymond Wong,Xiaoyan Ke,Alexander Fossa,David Simpson,Angela Dispenzieri,Mary Jo Lechowicz,John Kuruvilla,Rajesh Bandekar,Xiang Qin,Ming Qi,Jessica Vermeulen,Corey Casper

DOI: https://doi.org/10.1200/jco.2014.32.15_suppl.8514

IF: 45.3

2014-01-01

Journal of Clinical Oncology

Abstract:8514 Background: Siltuximab is a chimeric anti−IL-6 monoclonal antibody under investigation for treatment of MCD.A randomized, double-blind, placebo-controlled study in MCD showed significant improvement in durable tumor and symptomatic response (34.0% vs 0.0% with placebo; P = 0.001), superior response in the secondary endpoints of tumor response rate, time to treatment failure, MCD symptom improvement, and no increased frequency of adverse events compared with placebo. A prespecified subanalysis evaluated the efficacy of siltuximab among patients who had received prior systemic therapy. Methods: Adults with confirmed symptomatic MCD were randomized 2:1 to siltuximab 11 mg/kg (n = 53) or placebo (n = 26) IV every 3 weeks and were stratified by corticosteroid use at randomization. All patients received best supportive care, and treatment was continued until treatment failure. Results: The majority (siltuximab, n = 29 [54.7%]; placebo, n = 17 [65.4%]) of patients had received prior systemic treatment for MCD. The most frequently used agents included corticosteroids 93.5%, cyclophosphamide 50%, vincristine 26.1% and rituximab 17.4%. Durable tumor and symptomatic responses were similar for pretreated and treatment naïve subgroups (34.5 % vs 0% and 33.3 % vs 0% respectively). Secondary endpoints consistently favored siltuximab in both subgroups as presented in the Table. Frequencies of adverse events (AE) and serious (S) AEs were similar across pretreated and treatment naive subjects. Conclusions: Siltuximab is an active agent in both newly diagnosed MCD and patients who have insufficient response to or failed other therapies. Clinical trial information: NCT01024036. Pretreated MCD patients Treatment naïve MCD patients Siltuximab Placebo Siltuximab Placebo n 29 17 24 9 Durable tumor and symptom response by investigator 48% 0% 42% 0% Median time to treatment failure Not reached 184 days Not reached 177 days Hemoglobin increase > 1.5 g/dL in anemic subjects 59% (n = 17) 0% (n = 7) 64% (n = 14) 0% (n = 4) Durable complete symptomatic response 17% 0% 33% 0% Patients with AEs 100% 100% 100% 89% Patients with SAEs 24% 12% 21% 33%